FDA approves gene therapy for blood cancer in adults
- Share via
Reporting from Trenton, N.J. — U.S. regulators have approved a second gene therapy for blood cancer.
The one-time treatment is for aggressive lymphoma in adults.
The Food and Drug Administration approved sales of the therapy from Kite Pharma on Wednesday.
The treatment involves removing immune system cells called T cells from a patient, reprogramming them to target and kill cancer cells and giving them back to the patient. It uses the same technology as the first gene therapy approved in the United States, Novartis AG’s treatment for childhood leukemia.
Kite became a subsidiary of drugmaker Gilead Sciences this month. Gilead said the therapy will cost $373,000 per patient.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
